Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.

High-throughput screening of Tranzyme Pharma's proprietary macrocycle library using the aequorin Ca2+-bioluminescence assay against the human ghrelin receptor (GRLN) led to the discovery of novel agonists against this G-protein coupled receptor. Early hits such as 1 (Ki=86 nM, EC50=134 nM) though potent in vitro displayed poor pharmacokinetic properties that required optimization. While such macrocycles are not fully rule-of-five compliant, principally due to their molecular weight and clogP, optimization of their pharmacokinetic properties proved feasible largely through conformational rigidification. Extensive SAR led to the identification of 2 (Ki=16 nM, EC50=29 nM), also known as ulimorelin or TZP-101, which has progressed to phase III human clinical trials for the treatment of postoperative ileus. X-ray structure and detailed NMR studies indicated a rigid peptidomimetic portion in 2 that is best defined as a nonideal type-I' β-turn. Compound 2 is 24% orally bioavailable in both rats and monkeys. Despite its potency, in vitro and in gastric emptying studies, 2 did not induce growth hormone (GH) release in rats, thus demarcating the GH versus GI pharmacology of GRLN.

[1]  G. Tannenbaum,et al.  Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist. , 2008, Endocrinology.

[2]  M. Grossmann,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[3]  D. Veber,et al.  A super active cyclic hexapeptide analog of somatostatin. , 1984, Life sciences.

[4]  Daniel Fortin,et al.  Efficient parallel synthesis of macrocyclic peptidomimetics. , 2008, Bioorganic & medicinal chemistry letters.

[5]  S. Beauchemin,et al.  Discovery of a new class of macrocyclic antagonists to the human motilin receptor. , 2006, Journal of medicinal chemistry.

[6]  R. Bisschops,et al.  Influence of ghrelin on gastric emptying and meal‐related symptoms in idiopathic gastroparesis , 2005, Alimentary pharmacology & therapeutics.

[7]  H. Kessler,et al.  N-methylated cyclic pentaalanine peptides as template structures. , 2006, Journal of the American Chemical Society.

[8]  T. Peeters,et al.  Ghrelin: a new player in the control of gastrointestinal functions , 2005, Gut.

[9]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[10]  H. Wenschuh,et al.  The uronium/guanidinium Peptide coupling reagents: finally the true uronium salts. , 2002, Angewandte Chemie.

[11]  Han van de Waterbeemd,et al.  Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics , 2001 .

[12]  J. Holst,et al.  Ghrelin stimulates gastric emptying and hunger in normal-weight humans. , 2006, The Journal of clinical endocrinology and metabolism.

[13]  G. Rose,et al.  Turns in peptides and proteins. , 1985, Advances in protein chemistry.

[14]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[15]  J. Richardson,et al.  Principles and Patterns of Protein Conformation , 1989 .

[16]  A. Davenport,et al.  [125I‐His9]‐Ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue; up‐regulation of receptors with atherosclerosis , 2001 .

[17]  I. Popescu,et al.  The Ghrelin Agonist TZP-101 for Management of Postoperative Ileus After Partial Colectomy: A Randomized, Dose-Ranging, Placebo-Controlled Clinical Trial , 2010, Diseases of the colon and rectum.

[18]  Fibrosing NASH: on being a blind man in a dark room looking for a black cat (that isn't there). , 2011, Gastroenterology.

[19]  T. Schwartz,et al.  Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. , 2005, Molecular endocrinology.

[20]  Modulation of intrinsic phi,psi propensities of amino acids by neighbouring residues in the coil regions of protein structures: NMR analysis and dissection of a beta-hairpin peptide. , 1998, Journal of molecular biology.

[21]  A. Bondi.  van der Waals Volumes and Radii , 1964 .

[22]  A. Tonelli.  The effects of isolated N‐methylated residues on the conformational characteristics of polypeptides , 1976, Biopolymers.

[23]  R. Neubig,et al.  International Union of Pharmacology. LVI. Ghrelin Receptor Nomenclature, Distribution, and Function , 2005, Pharmacological Reviews.

[24]  D. Fairlie,et al.  Update 1 of: Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. , 2010, Chemical reviews.

[25]  P. Poitras,et al.  Ghrelin gastrokinetic action in patients with neurogenic gastroparesis , 2006, Peptides.

[26]  E. Søfteland,et al.  Safety and efficacy of ghrelin agonist TZP‐101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo‐controlled study , 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[27]  D. Trepanier,et al.  Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. , 1998, Clinical biochemistry.

[28]  D. Veber,et al.  NMR and molecular modeling characterization of RGD containing peptides. , 2009, International journal of peptide and protein research.

[29]  Stephen P. Hale,et al.  The exploration of macrocycles for drug discovery — an underexploited structural class , 2008, Nature Reviews Drug Discovery.

[30]  David A. Price,et al.  Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks , 2010 .

[31]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[32]  É. Marsault,et al.  Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. , 2011, Journal of medicinal chemistry.

[33]  Martin Poirier,et al.  Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. , 2004, Journal of medicinal chemistry.

[34]  G. Dollinger,et al.  Simultaneous On-Line Characterization of Small Organic Molecules Derived from Combinatorial Libraries for Identity, Quantity, and Purity by Reversed-Phase HPLC with Chemiluminescent Nitrogen, UV, and Mass Spectrometric Detection , 1998 .

[35]  J. Saunders,et al.  A screening library for peptide activated G-protein coupled receptors. 1. The test set. , 2004, Journal of medicinal chemistry.

[36]  Patrick R. Griffin,et al.  A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release , 1996, Science.

[37]  A. Moulin,et al.  Recent Developments in Ghrelin Receptor Ligands , 2007, ChemMedChem.

[38]  A. Chamberlin,et al.  Chemical Synthesis of Natural Product Peptides: Coupling Methods for the Incorporation of Noncoded Amino Acids into Peptides. , 1997, Chemical reviews.

[39]  R Marsault,et al.  Transfected Aequorin in the Measurement of Cytosolic Ca2+ Concentration ([Ca2+]c) , 1995, The Journal of Biological Chemistry.

[40]  L. Miller,et al.  Identification of Peptide Ligand-binding Domains within the Human Motilin Receptor Using Photoaffinity Labeling* , 2001, The Journal of Biological Chemistry.

[41]  L. Costantino,et al.  Ghrelin receptor modulators and their therapeutic potential. , 2009, Future medicinal chemistry.

[42]  F. Akhlaghi,et al.  Distribution of Cyclosporin in Organ Transplant Recipients , 2002, Clinical pharmacokinetics.

[43]  Richard L. Harlow,et al.  Structural Studies of a Family of High Affinity Ligands for GPIIb/IIIa , 1994 .

[44]  D. Cremer,et al.  Theoretical determination of molecular structure and conformation. 15. Three-membered rings: bent bonds, ring strain, and surface delocalization , 1985 .

[45]  A. Meijere.  Bonding Properties of Cyclopropane and Their Chemical Consequences , 1979 .

[46]  K. B. Wiberg.  Bent Bonds in Organic Compounds , 1996 .

[47]  Bernhard Pfeiffer,et al.  Over One Hundred Peptide‐Activated G Protein‐Coupled Receptors Recognize Ligands with Turn Structure , 2005 .

[48]  A. S. D. Miranda.  The Methylation Effect in Medicinal Chemistry , 2011 .

[49]  Ian A. Watson,et al.  Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.

[50]  Jose M Garcia,et al.  Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. , 2009, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[51]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[52]  J. Pezzullo,et al.  Randomised clinical trial: ghrelin agonist TZP‐101 relieves gastroparesis associated with severe nausea and vomiting – randomised clinical study subset data , 2011, Alimentary pharmacology & therapeutics.

[53]  R. Borchardt,et al.  Effect of Restricted Conformational Flexibility on the Permeation of Model Hexapeptides Across Caco-2 Cell Monolayers , 1997, Pharmaceutical Research.

[54]  K. Venkova,et al.  Prokinetic Effects of a New Ghrelin Receptor Agonist TZP-101 in a Rat Model of Postoperative Ileus , 2007, Digestive Diseases and Sciences.

[55]  V. Hruby,et al.  Design of Peptides, Proteins, and Peptidomimetics in Chi Space , 1997 .

[56]  P. Distefano,et al.  Enhanced Gastrointestinal Motility with Orally Active Ghrelin Receptor Agonists , 2009, Journal of Pharmacology and Experimental Therapeutics.

[57]  K. Venkova,et al.  Effect of the ghrelin receptor agonist TZP-101 on colonic transit in a rat model of postoperative ileus. , 2009, European journal of pharmacology.

[58]  M. Llinás,et al.  Solution conformation of the ferrichromes. VI. Charge relay at the peptide bond. Proton magnetic resonance study of solvation effects on the amide electron density distribution , 1975 .

[59]  Hoffmann.  Conformation Design of Open-Chain Compounds. , 2000, Angewandte Chemie.

[60]  M. Kamm,et al.  Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study , 2005, Gut.

[61]  G. N. Ramachandran,et al.  Conformation of polypeptides and proteins. , 1968, Advances in protein chemistry.

[62]  P. Y. Chou,et al.  Prediction of the secondary structure of proteins from their amino acid sequence. , 2006 .

[63]  J. Pezzullo,et al.  Ghrelin Agonist (TZP‐101): Safety, Pharmacokinetics and Pharmacodynamic Evaluation in Healthy Volunteers: A Phase I, First‐in‐Human Study , 2008, Journal of clinical pharmacology.

[64]  Christopher T. Walsh,et al.  Lessons from natural molecules , 2004, Nature.

[65]  J. Jørgensen.  A simple twist of science: the convoluted tale of ghrelin continues. , 2006, The Journal of clinical endocrinology and metabolism.